<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="438">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097719</url>
  </required_header>
  <id_info>
    <org_study_id>GMA-LUM-12-022</org_study_id>
    <nct_id>NCT02097719</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This efficacy and safety study will evaluate LUMIGAN® .01 (bimatoprost 0.01%) alone compared
      to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL GFS, 0.5% (timolol 0.5% ophthalmic gel
      forming solution) in patients who require IOP lowering therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM</measure>
    <time_frame>Week 12 at 8 AM, 12 PM, and 4 PM</time_frame>
    <safety_issue>No</safety_issue>
    <description>IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) is measured at 8 AM, 12 PM, and 4 PM. IOP is either the average of 2 measurements, or, if a third measurement is required, the average of 3 measurements.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>bimatoprost 0.01% and hypromellose 0.3%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>travoprost 0.004% and timolol 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost 0.01%</intervention_name>
    <description>Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.</description>
    <arm_group_label>bimatoprost 0.01% and hypromellose 0.3%</arm_group_label>
    <other_name>Lumigan® RC</other_name>
    <other_name>Lumigan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>travoprost 0.004%</intervention_name>
    <description>Travoprost 0.004% administered to both eyes once daily for 12 weeks.</description>
    <arm_group_label>travoprost 0.004% and timolol 0.5%</arm_group_label>
    <other_name>Travatan Z®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>timolol 0.5%</intervention_name>
    <description>Timolol 0.5% administered to both eyes once daily for 12 weeks.</description>
    <arm_group_label>travoprost 0.004% and timolol 0.5%</arm_group_label>
    <other_name>Timolol Maleate-EX</other_name>
    <other_name>Timolol GFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hypromellose 0.3%</intervention_name>
    <description>Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.</description>
    <arm_group_label>bimatoprost 0.01% and hypromellose 0.3%</arm_group_label>
    <other_name>GenTeal®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ocular hypertension or glaucoma that requires treatment with medication

          -  Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes

        Exclusion Criteria:

          -  History of LASIK, LASEK, RK, and/or PRK in the study eye(s)

          -  History of any intraocular surgery or glaucoma laser surgery in the study eye(s)
             within 3 months

          -  Use of topical, periorbital, intravitreal or systemic steroid within 3 months or
             expected use during the course of study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 9, 2015</lastchanged_date>
  <firstreceived_date>March 25, 2014</firstreceived_date>
  <firstreceived_results_date>December 9, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bimatoprost 0.01% and Hypromellose 0.3%</title>
          <description>Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Travoprost 0.004% and Timolol 0.5%</title>
          <description>Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bimatoprost 0.01% and Hypromellose 0.3%</title>
          <description>Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Travoprost 0.004% and Timolol 0.5%</title>
          <description>Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="49"/>
                <measurement group_id="B2" value="51"/>
                <measurement group_id="B3" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63.5" spread="11.73"/>
                <measurement group_id="B2" value="65.5" spread="9.98"/>
                <measurement group_id="B3" value="64.5" spread="10.86"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="46"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM</title>
        <description>IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) is measured at 8 AM, 12 PM, and 4 PM. IOP is either the average of 2 measurements, or, if a third measurement is required, the average of 3 measurements.</description>
        <time_frame>Week 12 at 8 AM, 12 PM, and 4 PM</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat: all subjects who were randomized to study medication with data at the noted time point</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost 0.01% and Hypromellose 0.3%</title>
            <description>Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Travoprost 0.004% and Timolol 0.5%</title>
            <description>Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM</title>
            <description>IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) is measured at 8 AM, 12 PM, and 4 PM. IOP is either the average of 2 measurements, or, if a third measurement is required, the average of 3 measurements.</description>
            <units>Millimeters of Mercury (mmHg)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 12 at 8 AM (N=46, 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.7" spread="0.50"/>
                  <measurement group_id="O2" value="15.4" spread="0.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 at 12 PM (N=46, 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.2" spread="0.43"/>
                  <measurement group_id="O2" value="15.6" spread="0.54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 at 4 PM (N=47, 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.0" spread="0.46"/>
                  <measurement group_id="O2" value="15.4" spread="0.60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bimatoprost 0.01% and Hypromellose 0.3%</title>
          <description>Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Travoprost 0.004% and Timolol 0.5%</title>
          <description>Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Medical Affairs,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
